Clinical Trial Update: Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating GLP-1 analogues to facilitate smoking cessation; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craving
• Smoking Cessation
• Weight Change Body

Drugs mentioned

• Glucagon-like peptide-1 analogue (GLP-1 analogue)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Glucagon-like Peptide-1, Smoking Cessation | Phase 2 | Status: COMPLETED